Technical Analysis for SNCA - Seneca Biopharma, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Up |
| Historical SNCA trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -0.64% | |
| Wide Bands | Range Expansion | -0.64% | |
| Wide Bands | Range Expansion | 5.41% | |
| Oversold Stochastic | Weakness | 5.41% | |
| Bullish Engulfing | Bullish | 0.65% | |
| Stochastic Buy Signal | Bullish | 0.65% | |
| Wide Bands | Range Expansion | 0.65% | |
| Oversold Stochastic | Weakness | 0.65% | |
| Narrow Range Bar | Range Contraction | 12.23% | |
| NR7 | Range Contraction | 12.23% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 3 hours ago |
| 50 DMA Resistance | about 3 hours ago |
| 60 Minute Opening Range Breakout | about 5 hours ago |
| Up 1% | about 5 hours ago |
| Down 3% | about 7 hours ago |
Get a Trading Assistant
- Earnings date: 04/23/2021
Seneca Biopharma, Inc. Description
Seneca Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidates include NSI-189, a chemical entity, which has been completed Phase II clinical trials for the treatment of major depressive disorder; and NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as in Phase II clinical trial for the treatment of chronic ischemic stroke and in Phase I clinical trial for the treatment of chronic spinal cord injury. The company was formerly known as Neuralstem, Inc. and changed its name to Seneca Biopharma, Inc. in October 2019. Seneca Biopharma, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Biology Stem Cells Injury Stroke Major Depressive Disorder Depressive Disorder Amyotrophic Lateral Sclerosis Spinal Cord Neuron Treatment Of Major Depressive Disorder Spinal Cord Injury Stem Cell Therapy Ischemic Stroke Antisense Therapy Chemical Entity
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.67 |
| 52 Week Low | 0.5001 |
| Average Volume | 3,650,530 |
| 200-Day Moving Average | 1.00 |
| 50-Day Moving Average | 1.59 |
| 20-Day Moving Average | 1.62 |
| 10-Day Moving Average | 1.53 |
| Average True Range | 0.19 |
| ADX | 21.16 |
| +DI | 26.56 |
| -DI | 18.57 |
| Chandelier Exit (Long, 3 ATRs ) | 2.11 |
| Chandelier Exit (Short, 3 ATRs ) | 1.90 |
| Upper Bollinger Band | 1.91 |
| Lower Bollinger Band | 1.33 |
| Percent B (%b) | 0.41 |
| BandWidth | 36.17 |
| MACD Line | -0.03 |
| MACD Signal Line | 0.00 |
| MACD Histogram | -0.0233 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.78 | ||||
| Resistance 3 (R3) | 1.76 | 1.68 | 1.74 | ||
| Resistance 2 (R2) | 1.68 | 1.62 | 1.68 | 1.73 | |
| Resistance 1 (R1) | 1.62 | 1.59 | 1.65 | 1.64 | 1.72 |
| Pivot Point | 1.54 | 1.54 | 1.55 | 1.55 | 1.54 |
| Support 1 (S1) | 1.48 | 1.48 | 1.51 | 1.50 | 1.42 |
| Support 2 (S2) | 1.40 | 1.45 | 1.41 | 1.41 | |
| Support 3 (S3) | 1.34 | 1.40 | 1.40 | ||
| Support 4 (S4) | 1.36 |
